The Eastern Network Kidney Inflammatory Disease (ENKID) MDT at 18 Months: Advancing Access to High-Cost Drugs, Clinical Trials, and Complex Case Management in renal autoimmunity. (UKKW 2025) - Jun 9, 2025 - Abstract #591; "A HCD (avacopan, belimumab, voclosporin, TR budesonide, rituximab) was endorsed in 75% of patient cases presented and alternatives recommended in 25%. High attendance and case load underscore the unmet need for this specialist service aligning with the UK government's mandate for rare autoimmune disease. We describe integration of this novel network within the existing renal regional network structure in the EOE, providing governance, training, access to HCDs and patient outcome reporting."
Clinical • ANCA Vasculitis • Chronic Kidney Disease • Complement-mediated Rare Disorders • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rare Diseases • Renal Disease • Rheumatology • Vasculitis
|
|
Dr Lucy Francis1; Olivia Kanka1; Dr Lisa Willcocks1; Dr Ondrej Suchanek1; Professor David Thomas1; Dr Kevin Loudon1; Mrs Clare Morlidge2; Dr Praveen Jeevaratnam2; Dr Barbara Thompson2; Professor David Jayne1; Dr Rona Smith1; Dr Rachel B Jones1
|